Skip Navigation


Cardiovascular Research Advance Access originally published online on June 26, 2008
Cardiovascular Research 2008 79(4):549-550; doi:10.1093/cvr/cvn176
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
79/4/549    most recent
cvn176v2
cvn176v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mehta, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehta, J. L.
Related Collections
Right arrowRelated Article
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

Erythropoietin in cardioprotection: does it have a future or is it all in the past?

Jawahar L. Mehta1,2,*

1 Division of Cardiovascular Medicine, Gene Therapy Program, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
2 Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA

* Corresponding author. Tel: +1 501 296 1401; fax: +1 501 686 6180. E-mail address: mehtajl@uams.edu

This editorial refers to ‘Post-infarct treatment with an erythropoietin–gelatin hydrogel drug delivery system for cardiac repair’ by H. Kobayashi et al.,1 pp. 611–620, this issue.

The first 10% of the full text of this article appears below.


   1. Introduction
 
Over the past two decades, we have seen a gradual reduction in mortality from myocardial infarction due in a large part to the advent of revascularization and other cardioprotective strategies. However, myocardial infarction is still the most common cause of morbidity, related primarily to the loss of left ventricular function and mortality. A host of novel strategies are being examined to limit myocardial infarct size. Towards that goal, several investigators have suggested that erythropoietin (EPO) therapy may hold a new promise. The article by Kobayashi et al. in the current issue of Cardiovascular Research describes a new drug delivery protocol for the use . . . [Full Text of this Article]


   2. Mechanisms of action of erythropoietin in myocardial infarction
 
2.1 Preclinical studies
2.2 Initial clinical studies
2.3 The present study

   3. Limitations of and concerns about therapy with erythropoiesis-stimulating agents
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article

Post-infarct treatment with an erythropoietin–gelatin hydrogel drug delivery system for cardiac repair
Hiroyuki Kobayashi, Shinya Minatoguchi, Shinji Yasuda, Narentuoya Bao, Itta Kawamura, Masamitsu Iwasa, Takahiko Yamaki, Syohei Sumi, Yu Misao, Hiroaki Ushikoshi, Kazuhiko Nishigaki, Genzou Takemura, Takako Fujiwara, Yasuhiko Tabata, and Hisayoshi Fujiwara
Cardiovasc Res 2008 79: 611-620. [Abstract] [Full Text] [PDF]